DK0646132T3 - Amino sugars, glycoproteins, processes for their preparation, drugs containing them and their use - Google Patents

Amino sugars, glycoproteins, processes for their preparation, drugs containing them and their use

Info

Publication number
DK0646132T3
DK0646132T3 DK94913578T DK94913578T DK0646132T3 DK 0646132 T3 DK0646132 T3 DK 0646132T3 DK 94913578 T DK94913578 T DK 94913578T DK 94913578 T DK94913578 T DK 94913578T DK 0646132 T3 DK0646132 T3 DK 0646132T3
Authority
DK
Denmark
Prior art keywords
immune system
glycoproteins
amino sugars
processes
preparation
Prior art date
Application number
DK94913578T
Other languages
Danish (da)
Inventor
Werner Reutter
Cora Schueler
Oliver Keppler
Michael Pawlika
Holger Kayser
Original Assignee
Werner Reutter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werner Reutter filed Critical Werner Reutter
Application granted granted Critical
Publication of DK0646132T3 publication Critical patent/DK0646132T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention pertains to new amino sugars (neuraminic acid precursor analogues) and new glycoproteins, methods of preparing them, pharmaceutical agents containing them and their use in stimulating growth and differentiation of human and animal cells of the immune system and in preventing the adhesion of leucocytes, thrombocytes and tumor cells to vascular endothelium cells, also in stimulating the immune system, especially T-lymphocytes, warding off infections and treating weaknesses in the immune system, tumorous illnesses including metastatic processes, infectious diseases (viruses, bacteria, parasites, protozoa) and circulatory failures, especially vascular occlusions and septicemia, in humans and animals.
DK94913578T 1993-04-12 1994-04-12 Amino sugars, glycoproteins, processes for their preparation, drugs containing them and their use DK0646132T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4311580A DE4311580C1 (en) 1993-04-12 1993-04-12 Glycoproteins, process for their preparation and pharmaceutical compositions containing them
PCT/EP1994/001126 WO1994024167A1 (en) 1993-04-12 1994-04-12 Amino sugars, glycoproteins, method of preparing them, medicines containing them and their use

Publications (1)

Publication Number Publication Date
DK0646132T3 true DK0646132T3 (en) 2000-03-13

Family

ID=6485046

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94913578T DK0646132T3 (en) 1993-04-12 1994-04-12 Amino sugars, glycoproteins, processes for their preparation, drugs containing them and their use

Country Status (8)

Country Link
EP (1) EP0646132B1 (en)
JP (1) JPH08501803A (en)
AT (1) ATE183204T1 (en)
AU (1) AU6567494A (en)
CA (1) CA2137833A1 (en)
DE (1) DE4311580C1 (en)
DK (1) DK0646132T3 (en)
WO (1) WO1994024167A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09183789A (en) * 1995-10-31 1997-07-15 Sanwa Kagaku Kenkyusho Co Ltd New sulfated and phosphated sugar derivative, its production and use
AUPP589398A0 (en) 1998-09-14 1998-10-08 Walter And Eliza Hall Institute Of Medical Research, The Immunogenic compositions and uses thereof
DE19852729A1 (en) 1998-11-16 2000-05-18 Werner Reutter Recombinant glycoproteins, processes for their preparation, medicaments containing them and their use
DE10045047A1 (en) 2000-09-12 2002-03-21 Beate Kehrel Medicament containing activated antithrombin III
US20050042714A1 (en) * 2001-08-17 2005-02-24 Michael Pawlita Glycoconjugates of sialic acid derivates, methods for their production and use thereof
DK1545599T3 (en) 2002-07-26 2015-08-03 Inst Medical W & E Hall IMMUNOGENIC PREPARATIONS AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS THEREOF
DE12193096T1 (en) * 2004-09-09 2013-07-25 Novartis Vaccines And Diagnostics Gmbh Reduce potential iatrogenic vaccine-related risks

Also Published As

Publication number Publication date
DE4311580C1 (en) 1994-08-18
WO1994024167A1 (en) 1994-10-27
CA2137833A1 (en) 1994-10-27
EP0646132A1 (en) 1995-04-05
ATE183204T1 (en) 1999-08-15
AU6567494A (en) 1994-11-08
EP0646132B1 (en) 1999-08-11
JPH08501803A (en) 1996-02-27

Similar Documents

Publication Publication Date Title
Djerassi et al. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer
PT82457A (en) Process for the preparation of pharmaceutical compound with base in phosphonil-methoxy-alkyl-adenines with antiviral activity
AU6642390A (en) Methods and compositions for promoting immunopotentiation
DE3684732D1 (en) ADOPTIVE IMMUNOTHERAPY AS A TREATMENT MODALITY IN PEOPLE.
BRPI0507822A (en) pharmaceutical method and composition for the prevention or treatment of a disease or an autoimmune or infectious condition, pharmaceutical method and composition for the prevention or treatment of a disease or a blood condition, pharmaceutical method and composition for modulating the formation of blood, method and pharmaceutical composition for enhancing peripheral stem cell mobilization, method and pharmaceutical composition for the prevention or treatment of a disease or metabolic condition, method and pharmaceutical composition for the prevention or treatment of conditions associated with myeloablative doses of chemotherapy supported by autologous bone marrow or peripheral blood stem cell transplantation (asct) or allogeneic bone marrow transplantation (bmt), pharmaceutical method and composition for enhancing the effect of a blood cell stimulating factor, pharmaceutical method and composition This is for enhancing colonization of donated blood stem cells into a myeloablated receptor, pharmaceutical composition and method for the prevention or treatment of a bacterial disease or condition, pharmaceutical composition for the treatment or prevention of a selected indication from the group consisting of in autoimmune disease or condition, viral disease, viral infection, hematologic disease, hematologic deficiencies, thrombocytopenia, pancytopenia, granulopenia, hyperlipidemia, hypercholesterolemia, glucosuria, hyperglycemia, diabetes, AIDS, hiv-1, helper t-cell disorders, dendritic cell deficiencies , macrophage deficiencies, hematopoietic stem cell disorders including platelet, lymphocyte, plasma cell and neutrophil disorders, pre-leukemic conditions, leukemic conditions, immune system disorders resulting from chemotherapy or radiation therapy, system disorders human immunodeficiency resulting from the treatment of diseases of immune deficiency and bacterial infections, pharmaceutical composition for the treatment or prevention of a selected indication from the group consisting of hematologic disease, hematologic deficiencies, thrombocytopenia, pancytopenia, granulopenia, dendritic cell deficiencies, macrophages, hematopoietic stem cell disorders including disorders with platelets, lymphocytes, plasma cells and neutrophils, pre-leukemic conditions, leukemic conditions, myelodysplastic syndrome, non-myeloid malignancies, plastic anemia and bone marrow insufficiency, purified peptide, purified chimeric peptide , chimeric peptide, pharmaceutical composition, pharmaceutical composition for the prevention or treatment of a condition associated with an infectious sars agent, proteolytic hydrolyzate low temperature processing method casein and casein protein hydrolyzate
SE9401406L (en) Pharmaceutical products for the cure of tumor diseases as well as a method for the preparation thereof
SE9201413L (en) Preparation and Methods for Apheresis Preparation of Platelet Concentrate with Significantly Extended Durability
STRINGFELLOW et al. Interferon induction by 5-halo-6-phenyl pyrimidinones
EP0308197A3 (en) Method for stimulating the immune system
DK0646132T3 (en) Amino sugars, glycoproteins, processes for their preparation, drugs containing them and their use
DE3650505T2 (en) AICA riboside for the prophylactic treatment of diseases with reduced blood flow.
Farnsworth Acute and subacute glomerulonephritis modified by adrenocorticotropin.
Werner-Wasik et al. Endogeneous interferon α/β produced by murine Kupffer cells augments liver-associated natural killing activity
AU5643299A (en) Humic acid and its use in the treatment of various conditions
Kudryashov et al. Action of defensin on healing of aseptic skin wounds and on vascular permeability
Alan et al. Interferon α/β selectively antagonises down-regulation of mannosyl-fucosyl receptors on activated macrophages by interferon γ
Kohl Stimulation of human natural killer cytotoxicity and protection of mice from infection due to herpes simplex virus by recombinant human leukocyte interferon
Alalawi et al. Combined effects of bleomycin and X-rays on DNA synthesis in asynchronous Ehrlich ascites cells in suspension
US4874608A (en) Therapeutic method for treating malignancies
Naoum et al. Treatment of herpes zoster with interferon alpha-2A.
SU1507380A1 (en) Method of treatment of hearing disorders
SU1600502A1 (en) Method of preparing erythrocyte diagnosticum for medicinal allergy indication to antibiotics
AU2366388A (en) A method for the preparation of a pharmaceutical curative for the veterinary and humane medicine, with antiviral and antitumoral effect
Neal et al. Pancoast tumor: radiation therapy alone versus preoperative radiation therapy and surgery.
STRINGFELLOW et al. Experimental Biology Research, The Upjohn Compary, Kalamazoo, MI 49001, USA Comparative Interferon-Inducing and Anti-Tumour Activity of Substituted Pyrimidinones